Our aim was to evaluate, in a remote Aboriginal community with high rates of renal and cardiovascular disease, whether episodes of acute post-streptococcal glomerulonephritis (PSGN) increase risk for chronic kidney disease in later life. Subjects were community members who participated in a health screen from [2004][2005][2006]. Albumin/creatinine ratios (ACRs) were measured on random urine samples and medical records were reviewed for histories of episodes of acute PSGN.
Introduction
Although now unusual in western countries and in Australia in general,(1) post-streptococcal glomerulonephritis (PSGN) is still common in Australia Aboriginal children living in remote communities, (2) (3) (4) (5) where scabies is common and group A streptococcal pyoderma is endemic.
PSGN occurs in both sporadic and epidemic forms. In these communities, chronic renal disease and end-stage renal failure also occur in adults at alarming rates. (6, 7) PSGN is usually followed by clinical recovery over several days to weeks, and the long-term outlook has generally been regarded as excellent, with no increase in risk of urinary abnormalities or hypertension. (8) (9) (10) However, some studies have suggested that there is an increase in chronic renal impairment after this illness. (11, 12) In one high risk Aboriginal community we described persisting urine abnormalities among 62 children who had symptomatic PSGN during specific epidemics in the 1980s,(4) and higher rates of microalbuminuria in people with a clinical history of PSGN at ages 15-29 years. (13) We now evaluate in that same community, the association of documented episodes of PSGN with albuminuria during a second community-wide conducted from 2004-2006, or more than 10 years later.
Results.
1519 people participated in the screening program, or about 85% of the age-eligible population. Of these, 200 had a history of PSGN recorded in their clinic charts: 173 had a single episode, and 27 had two or more episodes. Table 1 shows the numbers and proportions of people by sex and age group who had such a history. In all, 16.5% (n=92) of males and 19% of females (n=85) aged 5-39 years had a documented history of PSGN. Rates in people age >40 years at screening were lower than in younger people, and as noted above, they are excluded from further analyses.
Participants were then restricted to those age 10-39 years at examination, with ACR values available on the community screen. Those without a PSGN history were compared with those with a PSGN history recorded >5 years prior to the examination. These constituted 969 persons, of whom 177 (18.7%) had a PSGN history, >5 years earlier -16.5% of males and 20.7% of females, as shown in Table 2 . The table also shows that the PSGN episodes had usually occurred in childhood. The average time since the episodes for those age 20-29 years at screening was about 18 yr, and for those who were 30-39 yr olds at screening it was 25 yr. Table 3 compares some characteristics of those without and with a remote history of PSGN and those with on history of PSGN. Those with a PSGN history were somewhat older, on average, compatible with the major epidemics in the 1980s. There were no significant differences between the groups in BMI, blood pressure, CRP or lipid levels (apart from a lower LDL level in males with a PSGN history). Those with PSGN tended towards higher rates of diabetes than those without; however, this was not significant with adjustment for age, and HBA1c levels were not different. Among the "renal" indicators, average serum creatinine levels were higher in females with a remote history of PSGN than those without. In addition, people with a PSGN history tended towards higher rates of hematuria, had significantly higher rates of proteinuria by dipstick, had higher mean ACR levels and were more likely to have "elevated" levels of ACR by category than those without a PSGN history. It is noteworthy that most individuals with high ACR levels (> 34 mg/mmol) also had proteinuria, ie. 81% of males and 93% of females, with p<0.0001 for the association between the two in both sexes. Table 4 shows trends towards higher ACRs in those with a remote PSGN history in all age groups and in both sexes. There were no differences in e-GFR according to PSGN history in any age group in males, and none had e-GFR <60. However, in females age 30-39 years there was a trend towards lower eGFRs in those with a PSGN history, and 12% of that group had "low" GFR levels, which was significantly higher than the 0% in those without such a history (p=0.0003). Among people who were 20-39 years old at screening, neither the time since the PSGN episode nor the age at the PSGN episode were significant determinants of renal function at screening.
Discussion
Documented episodes of PSGN, both epidemic and sporadic, have been very common since 1970 in this Aboriginal group. In the mid 2000s, about 15% of adolescents (10-19 yr) and more than 20% of young adults (20-39 yr) had such a history recorded, with females equally or more often affected than males. In both sexes, those with a history of PSGN 5 or more years earlier, in whom acute inflammatory effects of PSGN should have subsided, had higher average levels of ACR than those without such a history, and were 3 to 4 times more likely to have elevated levels of ACR at the microalbuminuria and the overt albuminuria cutoffs. They also tended towards higher rates of proteinuria, and hematuria by dipstick. In addition, 12% of females age 30-39 yr with a remote PSGN history had low levels of e-GFR by the standard definition.
Thus PSGN contributes to the burden of CKD in this community. In view of the powerful predictive value of baseline levels of albuminuria for CKD progression and for both nonrenal and renal deaths, (14, 15) it must also contribute to this community's high rates of renal failure and premature nonrenal mortality.
The findings are consistent with the higher prevalence of microalbuminuria documented more than 10 years earlier in the same community in people age 15-29 years with a recorded PSGN history. (13) They are also compatible with a case-control study showing high levels of albuminuria in children who showing high rates of post-infectious GN and glomerulomegaly which presumably marks compensatory hypertrophy. (25, 26) Strengths of this study include the excellent ascertainment in the screen, the availability of the clinical records, the sweep of the historical information over 35 years, and the detailed knowledge of the distribution, associations and natural history of renal disease in this community. (13) (14) (15) The striking frequency of PSGN, and the high density of other nephropathic factors in this environment have probably helped educe the phenomenon. Weaknesses include the variable sensitivity to PSGN episodes over time, and failure to detect some cases of PSGN have probably resulted in underascertainment of its contribution to CKD. In hindsight, health workers comment that, in nonepidemic years and in the lead up to recognized epidemics, a child appearing "puffy" has sometimes not been further evaluated. In these settings, too, asymptomatic cases are entirely missed, although heightened consciousness and some targeted screening precipitated by symptomatic cases heralding epidemics result in more case-finding at those times. Undiagnosed cases probably contribute to some of the "unexplained" albuminuria in community members without a recognized PSGN history.
However, asymptomatic episodes are likely to be associated with a less serious acute course, as well as less marked long term consequences through lower levels of permanent nephron loss.
The data support the inclusion of PSGN as one vital factor in the multideterminant model of albuminuria. Such a model was first formulated in this community, (13) and is conceptually supported by the "multihit" hypothesis of renal disease later proposed by Nenoff and colleagues. (27) Other factors whose significant association with albuminuria we have modeled include age, lower birthweights, skin sores and scabies, non-skin infections (specifically with H. pylori), high CRP levels, levels of glycemia, lipids, current body weight and central fat deposition. (13, 28) The presence of a persistent specific antistreptococcal antibody, evaluated in a limited number of screened subjects, was also associated with higher levels of proteinuria, with the effect amplified by concurrent PSGN has been called a disease of transition. Previously these Aboriginal people lived in small groups, were nomadic and did not have permanent dwellings. Now they live in very crowded, poorly ventilated, poorly maintained, dirty houses, where scabies thrives and Group A streptococci spread easily. We cannot comment on the occurrence of PSGN prior to the observation period, but a community death register and, more recently, dialysis registries, suggest that renal failure has increased dramatically since the late 1970s. This, we propose, is fuelled in part by PSGN and infections related to crowding, poor hygiene and poor nutrition, while phenomena associated with lifestyle and health transition, and improved survival of low birthweight infants have also contributed.(30) Against this background of precipitating factors, the possibility of a genetic contribution to disease susceptibility is also being explored.
The frequency of PSGN in this era in a western country is astonishing. The elimination of scabies, the marker of the environment in which PSGN and other third world diseases flourish, must be a top priority in this and other remote communities. This is a matter of wholesale improvement across all sectors such as housing, nutrition and education. Justification could be provided based on cost savings in renal replacement therapy alone. The imminent trialling of anti-streptococcal vaccine could be extended to renal outcomes, rather than the exclusive rheumatic heart disease endpoints for which it was developed.(33) Nonetheless, the virtual elimination of PSGN in westernized environments was achieved without such a vaccine, and no less should be expected for Aboriginal people. Table 1 . Distribution of people with a history of PSGN, by age and sex Table 2 . Descriptive statistics for people with a remote history of PSGN (> 5 yr prior) Table 3 . Characteristics of subjects by a remote history of PSGN (> 5 years prior) by sex.
Mean (SD) except where otherwise specified. All p values reported are adjusted for age. Table 4 Renal parameters by a remote history of PSGN (>5 years prior) by sex and age group (number of participants in italics). Table 5 . Odds Ratios (95%CI) for renal parameters by history of remote PSGN (> 5 years prior) in people age 10-39 years at screening. Referrent group: people without a history of PSGN. 
